[A strategy for targeting gene therapy against cancer mediated by epidermal growth factor receptor]

To establish a protocol for the targeting gene therapy against cancer with rich epidermal growth factor receptor (EGFR).

A recombinant pcDNA3.1-PE III mut was constructed and combined with a non-viral vector, a fusion protein histone H1, epidermal growth factor C-loop previously expressed by us, to be a protein-DNA complex in vitro. Using the complex to treat BT-325 and Hela cancer cells with EGFR and JK cells without EGFR. The killing rates of the cells was calculated after 48 h of incubation at 37 degrees C.

To BT-325 and Hela cells, the killing rates were 46.03% and 48.12% respectively. To JK cells, the complex had no killing function.

The protocol for targeting gene therapy against cancer with EGFR has been established successfully.